Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a broad spectrum of malignancies. This new class of agents also challenges oncologists with a unique set of immune-based toxicities. Early recognition and precise management of these toxicities can result in better outcomes, with minimization of toxicity and harm to the patient. This article provides a comprehensive review of immune-based toxicities caused by immune checkpoint inhibitors, including recommendations for their investigation and guidelines for specific management.
CITATION STYLE
Roberts, K., Culleton, V., Lwin, Z., O’Byrne, K., & Hughes, B. G. M. (2017, August 1). Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pacific Journal of Clinical Oncology. Blackwell Publishing Ltd. https://doi.org/10.1111/ajco.12698
Mendeley helps you to discover research relevant for your work.